Abstract Body

Background

Without ART, HIV progresses rapidly in infants, with >50% mortality by age two. A rare subset of children living with perinatal HIV (CLH), termed pediatric slow progressors (SP), maintain high CD4 counts and low morbidity beyond age five without ART. Prior SP cohorts from South Africa, Europe, and Asia report low immune activation and minimal exhaustion. However, SP in East Africa remain poorly characterized, where viral subtypes and host genetics differ.

Methods

We analyzed a Kenyan cohort (ages 5–19, enrolled 2011–2012) of 40 children unexposed to HIV (CHU), 31 CLH virally suppressed on ART (ART+), and 42 ART-naïve CLH of which 12 met SP criteria defined by CD4 >750/mm³. Ten SP were age-matched 1:2 to ART-naïve progressors (PP), ART+ and CHU. High-dimensional flow cytometry quantified 127 innate (monocytes, DC, NK, MAIT, γδT) and adaptive (B, CD4, CD8, Tfh, Th1/2/17, Treg) subsets and markers of differentiation, activation (CD38, HLA-DR), exhaustion (PD-1, TIM-3, CD160, 2B4), proliferation (Ki67) and cytotoxicity (granzyme B, perforin). Plasma biomarkers (sCD14, sCD163, sCD40L, IFABP) were measured by ELISA. Statistical analyses used Kruskal-Wallis with FDR correction and post-hoc Dunn’s tests in R.

Results

Median age was 9.2 years (IQR 7.4–11); 43% were female; age and sex did not differ across groups. SP had CD4% (32, IQR 27–37) similar to ART+ and CHU, but higher than PP (15, IQR 7–24, p=0.005). SP had higher naïve (p=0.02) and lower memory (p=0.03) CD4 T cells than PP. Compared to CHU, SP had higher memory CD8 T cells (p=0.002), PD-1⁺ memory CD4 (p=0.004) and CD8 (p=0.04), CD38⁺HLA-DR⁺ CD4 (p=0.006) and CD8 (p=0.0003) and Ki67⁺ CD4 (p=0.004) and CD8 (p=0.00002). SP had higher CD38⁺HLA-DR⁺ CD8 (p=0.0005) and memory CD4 (p=0.04) and Ki67⁺ CD8 (p=0.0007) than ART+. Naïve CD4 T cells in SP expressed increased perforin and granzyme B (both p=0.002) than CHU. After HIV gag stimulation, SP had greater HIV-specific CD8 (p=0.01) but not CD4 proliferation than ART+.

Conclusions

Unlike prior SP cohorts, Kenyan SP show elevated activation, exhaustion, proliferation, and cytotoxicity despite preserved CD4 counts. However, SP retain robust HIV-specific CD8 T cell function, suggesting preserved effector capacity. As the first deep immune profiling of pediatric SP in East Africa, our findings highlight that preserved CD4 counts do not confer immunologic health in pediatric HIV and support universal ART. The distinct immune phenotype in Kenyan SP may reflect unique viral or host genetic factors.